AbCellera Biologics annual revenue
2019
2020
2021
2022
2023
2024
2025
AbCellera Biologics Revenue Growth & History (ABCL)
AbCellera Biologics reported $75.1M in revenue for fiscal 2025, an increase of 160.56% from the previous fiscal year.
View full AbCellera Biologics company overviewAbCellera Biologics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $75.1M | $46.3M | +160.56% |
| 2024 | 2024-12-31 | $28.8M | −$9.2M | −24.17% |
| 2023 | 2023-12-31 | $38.0M | −$447.4M | −92.17% |
| 2022 | 2022-12-31 | $485.4M | $110.2M | +29.38% |
| 2021 | 2021-12-31 | $375.2M | $142.0M | +60.92% |
| 2020 | 2020-12-31 | $233.2M | $221.5M | +1907.88% |
| 2019 | 2019-12-31 | $11.6M | — | — |
AbCellera Biologics quarterly revenue
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.0M | −$13.0M | −76.29% |
| Q1 2026 | 2026-03-31 | $8.3M | $4.1M | +96.34% |
| Q4 2025 | 2025-12-31 | $44.9M | $39.8M | +788.37% |
| Q3 2025 | 2025-09-30 | $9.0M | $2.4M | +37.62% |
| Q2 2025 | 2025-06-30 | $17.1M | $9.8M | +133.29% |
| Q1 2025 | 2025-03-31 | $4.2M | −$5.7M | −57.45% |
| Q4 2024 | 2024-12-31 | $5.0M | −$4.1M | −44.99% |
| Q3 2024 | 2024-09-30 | $6.5M | −$92,000 | −1.39% |
| Q2 2024 | 2024-06-30 | $7.3M | −$2.7M | −27.18% |
| Q1 2024 | 2024-03-31 | $10.0M | −$2.2M | −18.36% |
| Q4 2023 | 2023-12-31 | $9.2M | −$12.4M | −57.40% |
| Q3 2023 | 2023-09-30 | $6.6M | −$94.8M | −93.49% |
| Q2 2023 | 2023-06-30 | $10.1M | −$35.9M | −78.10% |
| Q1 2023 | 2023-03-31 | $12.2M | −$304.4M | −96.15% |
| Q4 2022 | 2022-12-31 | $21.5M | −$117.8M | −84.54% |
| Q3 2022 | 2022-09-30 | $101.4M | $95.9M | +1740.65% |
| Q2 2022 | 2022-06-30 | $45.9M | $18.3M | +66.11% |
| Q1 2022 | 2022-03-31 | $316.6M | $113.8M | +56.15% |
| Q4 2021 | 2021-12-31 | $139.3M | −$68.6M | −32.99% |
| Q3 2021 | 2021-09-30 | $5.5M | −$3.9M | −41.17% |
| Q2 2021 | 2021-06-30 | $27.6M | $16.4M | +146.20% |
| Q1 2021 | 2021-03-31 | $202.7M | $198.1M | +4253.47% |
| Q4 2020 | 2020-12-31 | $207.9M | — | — |
| Q3 2020 | 2020-09-30 | $9.4M | — | — |
| Q2 2020 | 2020-06-30 | $11.2M | — | — |
| Q1 2020 | 2020-03-31 | $4.7M | — | — |
AbCellera Biologics revenue growth trends
Over the last five reported fiscal years, revenue declined from $233.2M to $75.1M, a compound annual decline of 20.27%. AbCellera Biologics's latest reported quarter, Q2 2026, generated $4.0M in revenue, a decrease of 76.29% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review AbCellera Biologics source filings ↗